Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.

Journal of medicinal chemistry - 22 Oct 2020

Yuan Xinrui, Bu Hong, Zhou Jinpei, Yang Chao-Yie, Zhang Huibin

Abstract excerpt

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally, SHP2 serves as an important hub to connect several intracellular oncogenic signaling pathways, such as Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1 pathways. Mutations and/or overexpression of SHP2 has been associated with genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Drug Development

Share to Enzyme Inhibitors

Share to Molecular Structure

Share to Neoplasms

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Identifiers

PMID: 32460492
DOI: 10.1021/acs.jmedchem.0c00249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.PMID 32460492Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.Semantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.Semantic proximity Read ↗

Functions of Shp2 in cancer.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.